Application 1014
Transurethral needle ablation (TUNA) for the treatment of benign prostatic hyperplasia
|
Application No. | 1014 |
| Application Name | Transurethral needle ablation (TUNA) for the treatment of benign prostatic hyperplasia |
| Advisory Panels | Dr Michael Kitchener (Chair and MSAC member) Dr Ross Cartmill (Urological Society of Australasia nominee) Mr Alan Crosthwaite (Royal Australasian College of Surgeons and the Urological Society of Australia nominee) Dr Brian Kable (Royal Australian College of General Practitioners nominee) Professor Vills Marshall (co-opted member) Mr Don Thomson (Continence Foundation nominee) |
| Date Received by MSAC Secretariat | 1 March 1999 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 6 March 2002 meeting. Based on the evidence available, while safe and efficacious in the short term, the long term effectiveness and cost-effectiveness of TUNA has not been proven. The MSAC therefore concludes that unrestricted Medicare Benefits Scheme funding of TUNA for the surgical management of symptomatic benign prostatic hyperplasia is not warranted at this time. TUNA may, however, have a limited role as an alternative treatment for symptomatic benign prostatic hyperplasia with the following restrictions:
|
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 17 May 2002 |
| Stage 5 - Implementation | Implemented |
Page currency, Latest update: 06 July, 2009
